BioCentury
ARTICLE | Clinical News

AT7519: Phase I data

April 20, 2009 7:00 AM UTC

In a dose-escalation, international Phase I trial in patients with refractory solid tumors, 3.6-34 mg/m 2/day of IV AT7519 inhibited CDK as assessed by a reduction in phospho- nucleophosmin and prolif...